Clinical Update on the Intersection of Lipoprotein(a) and Calcific Valve Disease

Purpose of Review: To critically review the literature and summarize the available evidence to better understand the association of Lipoprotein(a) [Lp(a)] and calcific valve disease. Recent Findings: Serum Lp(a) is a causal and independent biomarker associated with atherosclerotic cardiovascular disease (ASCVD) with many direct Lp(a) targeting therapeutics in clinical trials. Lp(a) has also been associated with calcific valve disease, but with far less literature. The pathophysiology of valve calcifications has some key differences to the pathophysiology of ASCVD, both biochemically and genetically. Summary: In this review we summarize the current literature on the association of Lp(a) and calcific valve disease, pathophysiology, genetics and future areas of study. Additionally, we also provide guidance based on available evidence on Lp(a) screening in the context of calcific valve disease.

Duke Scholars

Author Nishant Shah Medicine, Cardiology

Author Neha Pagidipati Medicine, Cardiology